相关实验视频
Updated: Jan 6, 2026
12:03
In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis
Published on: December 9, 2016
12.8K
KC1036在Ewing肉瘤:机械的见解和未来的方向为一个多目标的治疗策略
Du Jiang Yang1,2, Lin Yang1, Jiexiang Yang1
1The Affiliated Traditional Chinese Medicine Hospital,Southwest Medical University, NO.182, Chunhui Road, Longmatan District, Luzhou, Sichuan Province, 646000, People's Republic of China.
Angiogenesis
|October 18, 2025
概括
多酶抑制剂KC1036通过向血管生长和瘤细胞,在临床前尤宁肉瘤 (ES) 研究中显示出有前途. 需要进一步的研究,以了解其全部潜力,并确保临床成功.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 尤文肉瘤 (ES) 是一种具有攻击性的骨和软组织癌症,治疗选择有限.
- 目前的疗法面临着由于治疗耐药性和疾病复发的挑战.
- 针对血管新生和直接的瘤细胞增殖,为ES提供了一个合理的治疗策略.
研究的目的:
- 在尤文肉瘤中批判性地分析多酶抑制剂KC1036的临床前疗效.
- 评估KC1036.3的双重抗血管生成和直接抗瘤机制.
- 确定ES中KC1036的临床翻译的未来研究重点.
主要方法:
- 对Ou等人临床前数据的批判性评估. (血管新生,2025年).
- 专注于抑制血管内皮生长因子受体 (VEGFR) 和纤维细胞生长因子受体 (FGFR) 信号传递.
- 在ES的病原和抗药机制中进行上下文化.
主要成果:
- 通过同时抑制VEGFR和FGFR信号传递,KC1036有效地抑制了尤文肉瘤的生长.
- 这项研究表明,KC1036.的抗血管和直接抗瘤作用.
- 临床前数据表明,KC1036是ES的强有力的治疗候选者.
结论:
- KC1036代表了一种有前途的多酶抑制剂,用于尤宁肉瘤治疗.
- 需要进一步研究以阐明其精确的分子机制和与EWSR1-FLI1瘤基因的相互作用.
- 确定耐药性路径和评估治疗指数对于成功的临床转化至关重要.
相关概念视频
02:57Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
02:38Mitogens and the Cell Cycle
7.6K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.6K
02:50Combination Therapies and Personalized Medicine
5.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K
02:15M-Cdk Drives Transition Into Mitosis
6.2K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
6.2K